Found: 23
Select item for more details and to access through your institution.
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 8, p. 1620, doi. 10.1002/ajh.27367
- By:
- Publication type:
- Article
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 6, p. 1192, doi. 10.1002/ajh.27304
- By:
- Publication type:
- Article
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 12, p. 1679, doi. 10.1002/ajh.26367
- By:
- Publication type:
- Article
Health‐related quality of life with fixed‐duration venetoclax‐obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 9, p. 1112, doi. 10.1002/ajh.26260
- By:
- Publication type:
- Article
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 9, p. 1002, doi. 10.1002/ajh.25561
- By:
- Publication type:
- Article
Targeted Therapy of CLL.
- Published in:
- Oncology Research & Treatment, 2016, v. 39, n. 12, p. 768, doi. 10.1159/000452786
- By:
- Publication type:
- Article
Nrf2 Protects Against TWEAK-mediated Skeletal Muscle Wasting.
- Published in:
- Scientific Reports, 2014, p. 1, doi. 10.1038/srep03625
- By:
- Publication type:
- Article
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-37648-w
- By:
- Publication type:
- Article
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-37648-w
- By:
- Publication type:
- Article
Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 3, p. 254, doi. 10.1111/ejh.12825
- By:
- Publication type:
- Article
Chronische lymphatische Leukämie.
- Published in:
- Der Internist, 2020, v. 61, n. 3, p. 277, doi. 10.1007/s00108-019-00733-8
- By:
- Publication type:
- Article
How I Use MRD: European and American Perspectives.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S119, doi. 10.1016/S2152-2650(21)01234-9
- By:
- Publication type:
- Article
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 8, p. 3635, doi. 10.1007/s12325-022-02170-w
- By:
- Publication type:
- Article
Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
- Published in:
- Current Oncology Reports, 2024, v. 26, n. 2, p. 136, doi. 10.1007/s11912-023-01482-6
- By:
- Publication type:
- Article
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy.
- Published in:
- Drug Design, Development & Therapy, 2017, v. 11, p. 295, doi. 10.2147/DDDT.S104869
- By:
- Publication type:
- Article
A Novel Laser-Doppler Flowmetry Assisted Murine Model of Acute Hindlimb Ischemia-Reperfusion for Free Flap Research.
- Published in:
- PLoS ONE, 2013, v. 8, n. 6, p. 1, doi. 10.1371/journal.pone.0066498
- By:
- Publication type:
- Article
Nrf2 augments skeletal muscle regeneration after ischaemia-reperfusion injury.
- Published in:
- Journal of Pathology, 2014, v. 234, n. 4, p. 538, doi. 10.1002/path.4418
- By:
- Publication type:
- Article
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 5, p. 727, doi. 10.1111/bjh.15604
- By:
- Publication type:
- Article
The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 2, p. 97
- By:
- Publication type:
- Article
Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.
- Published in:
- Therapeutic Advances in Hematology, 2017, v. 8, n. 6, p. 197, doi. 10.1177/2040620717699365
- By:
- Publication type:
- Article
Nrf2 in health and disease: current and future clinical implications.
- Published in:
- Clinical Science, 2015, v. 129, n. 12, p. 989, doi. 10.1042/CS20150436
- By:
- Publication type:
- Article
Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia.
- Published in:
- Acta Haematologica, 2024, v. 147, n. 1, p. 24, doi. 10.1159/000534846
- By:
- Publication type:
- Article